Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2015

Description: Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2015

Summary

The report ‘Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2015’, provides an overview of the Gastrointestinal Stromal Tumor (GIST)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Gastrointestinal Stromal Tumor (GIST), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastrointestinal Stromal Tumor (GIST) and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumor (GIST)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Gastrointestinal Stromal Tumor (GIST) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Gastrointestinal Stromal Tumor (GIST) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Gastrointestinal Stromal Tumor (GIST) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for
Gastrointestinal Stromal Tumor (GIST)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Gastrointestinal Stromal Tumor (GIST) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:
List of Tables
List of Figures
Introduction
Report Coverage
Gastrointestinal Stromal Tumor (GIST) Overview
Therapeutics Development
Pipeline Products for Gastrointestinal Stromal Tumor (GIST) - Overview
Pipeline Products for Gastrointestinal Stromal Tumor (GIST) - Comparative Analysis
Gastrointestinal Stromal Tumor (GIST) - Therapeutics under Development by Companies
Gastrointestinal Stromal Tumor (GIST) - Therapeutics under Investigation by Universities/Institutes
Gastrointestinal Stromal Tumor (GIST) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Gastrointestinal Stromal Tumor (GIST) - Products under Development by Companies
Gastrointestinal Stromal Tumor (GIST) - Products under Investigation by Universities/Institutes
Gastrointestinal Stromal Tumor (GIST) - Companies Involved in Therapeutics Development
AB Science SA
Advenchen Laboratories, LLC
Ariad Pharmaceuticals, Inc.
Arog Pharmaceuticals, Inc.
Array BioPharma Inc.
Astex Pharmaceuticals, Inc.
Blueprint Medicines
Boston Biomedical, Inc.
Calithera Biosciences, Inc.
Chipscreen Biosciences Ltd
Deciphera Pharmaceuticals, LLC
F. Hoffmann-La Roche Ltd.
Immunicum AB
Jiangsu Hengrui Medicine Co., Ltd.
Natco Pharma Limited
Nerviano Medical Sciences S.r.l.
Novartis AG
Omeros Corporation
Plexxikon Inc.
Synta Pharmaceuticals Corp.
Takeda Pharmaceutical Company Limited
TG Therapeutics, Inc.
Threshold Pharmaceuticals, Inc.
Gastrointestinal Stromal Tumor (GIST) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
alpelisib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
apatinib - Drug Profile
Product Description
Product Description
Mechanism of Action
R&D Progress
onalespib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pexidartinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PLX-9486 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ponatinib hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SF-1126 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SHR-1020 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Antagonize GPR20 for Gastro-Intestinal Stromal Tumors and Acute Myeloid Leukemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit c-Kit for Gastrointestinal Stromal Tumor - Drug Profile

Product Description
Mechanism of Action
R&D Progress
TGR-1202 - Drug Profile
Product Description
Mechanism of Action
R&D Progress

vemurafenib - Drug Profile
Product Description
Mechanism of Action
R&D Progress

Gastrointestinal Stromal Tumor (GIST) - Recent Pipeline Updates
Gastrointestinal Stromal Tumor (GIST) - Dormant Projects
Gastrointestinal Stromal Tumor (GIST) - Discontinued Products
Gastrointestinal Stromal Tumor (GIST) - Product Development Milestones

Featured News & Press Releases

Jul 13, 2015: Blueprint Medicines Receives FDA Authorization to Proceed with Clinical Trials for BLU-285

Apr 19, 2015: Blueprint Medicines Presents New Preclinical Data Demonstrating Significant Anti-Tumor Activity of BLU-285 in Treatment-Resistant GIST and on Novel Cancer Drug Targets

Apr 08, 2015: Blueprint Medicines to Present New Preclinical Data on BLU-285 in Treatment-Resistant GIST and on Novel Cancer Drug Targets at Upcoming AACR Annual Meeting

Jun 01, 2014: ARIAD Announces Initial Data from Phase 2 Trial of Ponatinib in Patients with Gastrointestinal Stromal Tumors

Mar 20, 2014: CHMP Adopts Negative Opinion For AB Science's Masican

Oct 09, 2013: ARIAD Announces Changes in the Clinical Development Program of Iclusig

Jun 11, 2013: Ariad Pharma Initiates Phase II Trial Of Ponatinib In Patients With Gastrointestinal Stromal Tumors

Jun 02, 2013: Threshold Pharma Announces Data From Two Ongoing Phase I/II Trials Of TH-302 At 2013 ASCO Annual Meeting

Apr 09, 2013: Ariad Pharma Presents New Preclinical Data Showing Ponatinib Overcomes Resistant Mutations In Oncogenic Driver Of Gastrointestinal Stromal Tumors

Mar 20, 2013: Ariad Pharma Announces Presentations Of Preclinical Data On Iclusig At ACR Annual Meeting

Appendix
Methodology
Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H2 2015
Number of Products under Development for Gastrointestinal Stromal Tumor (GIST) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015
Gastrointestinal Stromal Tumor (GIST) - Pipeline by AB Science SA, H2 2015
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Advenchen Laboratories, LLC, H2 2015
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Ariad Pharmaceuticals, Inc., H2 2015
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Arog Pharmaceuticals, Inc., H2 2015
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Array BioPharma Inc., H2 2015
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Astex Pharmaceuticals, Inc., H2 2015
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Blueprint Medicines, H2 2015
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Boston Biomedical, Inc., H2 2015
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Calithera Biosciences, Inc., H2 2015
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Chipscreen Biosciences Ltd, H2 2015
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2015
Gastrointestinal Stromal Tumor (GIST) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Immunicum AB, H2 2015
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2015
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Natco Pharma Limited, H2 2015
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Nerviano Medical Sciences S.r.l., H2 2015
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Novartis AG, H2 2015
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Omeros Corporation, H2 2015
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Plexxikon Inc., H2 2015
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Synta Pharmaceuticals Corp., H2 2015
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015
Gastrointestinal Stromal Tumor (GIST) - Pipeline by TG Therapeutics, Inc., H2 2015
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Threshold Pharmaceuticals, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Gastrointestinal Stromal Tumor (GIST) Therapeutics - Recent Pipeline Updates, H2 2015
Gastrointestinal Stromal Tumor (GIST) - Dormant Projects, H2 2015
Gastrointestinal Stromal Tumor (GIST) - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H2 2015
Number of Products under Development for Gastrointestinal Stromal Tumor (GIST) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Ordering:

Order Online - http://www.researchandmarkets.com/reports/3548612/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2015
Web Address: http://www.researchandmarkets.com/reports/3548612/
Office Code: SCD23GCR

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprise wide</td>
<td></td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title:  Mr  [ ]  Mrs  [ ]  Dr  [ ]  Miss  [ ]  Ms  [ ]  Prof  [ ]
First Name: ___________________________  Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB9853308313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: ________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp